To reduce the mortality from ovarian cancer various studies by transvaginal color Doppler (TVCD) sonography and serum CA-125 tumor marker, alone or in combination, have been performed. Relatively poor specificities of CA-125 and transvaginal conventional sonography can be improved with the use of TVCD. Furthermore, high specificity can be achieved on screening asymptomatic postmenopausal women by combining serum CA-125 measurement with TVCD. Combining tests should not necessarily increase the overall cost of screening because of the expected decrease in the number of unnecessary surgical interventions. Until the results of large, prospective studies are available, the efficacy of potential tests for screening of ovarian cancer will remain unproven and they should not be used to screen apparently healthy women outside of scientific interest.